AI Article Synopsis
- CAR T-cell therapy is a novel treatment that has significantly improved outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
- There are two FDA-approved CAR-T products specifically for this condition: tisagenlecleucel for patients under 26 and brexucabtagene autoleucel for those 18 and older.
- The review discusses key clinical trials for these therapies, ongoing research addressing treatment strategies, and the potential future developments in CAR-T therapy to enhance patient care.
Article Abstract
CAR T-cell therapy is a recent therapeutic advancement that has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To date, there are 2 FDA-approved CAR-T products for R/R B-ALL: tisagenlecleucel in patients aged <26 years and brexucabtagene autoleucel in those aged ≥18 years. This review summarizes the pivotal clinical trials that led to FDA approval of these 2 products and highlight emerging data addressing key questions pertinent to CAR-T utilization in the rapidly evolving landscape of R/R ALL management. These include optimal sequencing of CAR-T among other novel immunotherapeutic agents, the role of consolidation and maintenance following CAR-T, novel CAR-T constructs currently under clinical development, and strategies to optimize use of commercially available CAR-T products to improve patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2024.7065 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!